CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD 172.32
-1.56 (-0.90%)
Aug 28, 2026, 4:10 PM AEST
CSL Limited Employees
CSL Limited had 29,000 employees as of June 30, 2026. The number of employees decreased by 904 or -3.02% compared to the previous year.
Employees
29,000
Change (1Y)
-904
Growth (1Y)
-3.02%
Revenue / Employee
787.40K AUD
Profits / Employee
-128.55K AUD
Market Cap
83.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 29,000 | -904 | -3.02% |
| Jun 30, 2025 | 29,904 | -2,794 | -8.54% |
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Clarity Pharmaceuticals | 88 |
| Mesoblast | 81 |
| Starpharma Holdings | 40 |
| Tetratherix | 25 |
CSL Limited News
- 10 days ago - CSL Limited Earnings Call Transcript: H2 2026 - Transcripts
- 10 days ago - CSL Limited Slides: H2 2026 - Filings
- 10 days ago - CSL Limited Earnings release: H2 2026 - Filings
- 10 days ago - CSL Limited Annual report: H2 2026 - Filings
- 10 days ago - Australia's CSL reports 2% fall in annual profit - Reuters
- 4 weeks ago - CSL to start clinical trials for new immunoglobulin manufacturing process - Reuters
- 4 weeks ago - CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union - PRNewsWire